🔬Deep Research

CDXS — Codexis Inc · catalysts, narrative & risks

·25 sourcesCDXS forecast →

Codexis Inc. (NASDAQ: CDXS) — Research Notes as of 2026-10-17

Point-in-time findings from the sources below. Not investment advice.

Company Snapshot

Codexis is a Redwood City, California–based protein-engineering/biocatalysis company (founded 2002, IPO'd 2010) that runs two platforms: the CodeEvolver directed-evolution/AI engine and the ECO Synthesis RNA-manufacturing platform for siRNA [3][14][22][26]. It reports in two segments — Performance Enzymes (pharma biocatalysis) and Novel Biotherapeutics (RNA) [18]. Market data as of the Oct 16, 2026 close: stock price ~$1.24, down roughly −24% YTD and about −53% over the trailing year, versus a 52-week range of ~$0.96–$2.98 and a beta of 2.55 [9][14][16].


AI-assisted research from the K3vl4r desk — not personalized investment advice. More research →